Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes

Bibliography

• SOWERS JR, EPSTEIN M: Diabetes mellitus and associ-ated hypertension, vascular disease and nephropathy. Hypertension (1995) 26:869–879.
   PubMed Web of Science ®Google Scholar
• MOGENSEN C-E: Natural history of cardiovascular and renal disease in patients with Type 2 diabetes: Effect of therapeutic interventions and risk modifications. Am. Cardiol. (1998) 82:4R–8R.
   Google Scholar
• RITZ E, ORTH SR: Nephropathy in patients with Type 2diabetes. N Eng]. J. Med. (1999) 341:1127–1133.
   PubMed Web of Science ®Google Scholar
• HYPERTENSION IN DIABETES STUDY GROUP HDS 1: Prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. (1993) 11:309–317.
   PubMed Web of Science ®Google Scholar
• CURB JD, PRESSEL SL, CUTLER JA et al: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA (1996) 276:1886–1892.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: UK Prospective Diabetes Study 23: risk factors for coronary artery disease in non-insulin dependent diabetes. BMJ (1998) 316:823–828.
   PubMed Web of Science ®Google Scholar
• STAMLER J, VACCARO 0, NEATON J, WENTVVORTH D: Diabetes, other risk factors and I2-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 16:434–444.
   PubMed Web of Science ®Google Scholar
• MANSON J, COLDLITZ G, STAMPFER M: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch. Intern. Med. (1991) 151:1141–1147.
   PubMed Web of Science ®Google Scholar
• MOSS SE, KLEIN R, KLEIN BE: Cause-specific mortality in a population-based study of diabetes. Am. J Public Health (1991) 81:1158–1162.
   PubMed Web of Science ®Google Scholar
• RITZ E, STEFANSKI A: Diabetic nephropathy in Type II diabetes. Am. J. Kidney Dis. (1996) 27:167–194.
   PubMed Web of Science ®Google Scholar
• GALL M-A B-JK, HOUGAARD P, NIELSEN FS, PARVING H-H: Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes (1995) 44:1303–1309.
   PubMed Web of Science ®Google Scholar
• PARVING H-H: Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia (1998) 41:745–759.
   PubMed Web of Science ®Google Scholar
• DZAU VJ: Significance of the vascular renin-angiotensin pathway. Hypertension (1986) 8:553–559.
   PubMed Web of Science ®Google Scholar
• HARRIS R, CHENG H-F: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp. Nephrol (1996) 4:2–7.
   PubMedGoogle Scholar
• ANDERSON S: Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner. Electrolyte Metab. (1998) 24:406–411.
   PubMedGoogle Scholar
• TSUZUKI S, MATOBA T, EGUCHI S, INAGAMI T: Angiotensin II Type 2 receptor inhibits cell prolifera-tion and activates tyrosine phosphatase. Hypertension (1996) 28:916–918.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA M, HUTCHINSON HG, FUGINAGA M et al.: The angiotensin II Type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA (1995) 82:10663–10667.
   Google Scholar
• JANIAK P, PILLON A, PROST JF, VILAINE JP: Role of angiotensin subtype 2 receptor in n coin tima formation after vascular injury. Hypertension (1992) 20:737–745.
   PubMed Web of Science ®Google Scholar
• MORRISSEY JJ, KLAHR S: Effect of AT2 receptor blockadeon the pathogenesis of renal fibrosis. Am. J Physiol (1999) 276:F39–F45.
   PubMed Web of Science ®Google Scholar
• MA J, NISHIMURA H, FOGO A, KON V, INAGAMI T, ICHIKAWA I: Accelerated fibrosis and collagen deposi-tion develop in the renal interstitium of angiotensin Type II receptor knock-out mouse. Kidney Int. (1998) 53:937–944.
   PubMed Web of Science ®Google Scholar
• LEVY BI, BENESSIANO J, HENRION D et al.: Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin. Invest. (1996) 98:418–425.
   PubMed Web of Science ®Google Scholar
• HUNLEY TE, MASAAKI T, STONEKING BJ et al.: The angiotensin Type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice. Kidney Int. (2000) 57:570–577.
   PubMed Web of Science ®Google Scholar
• LIU Y-H, YANG X-P, SHAROV VG et al.: Effects of angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II Type 2 receptors. J Clin. Invest. (1997) 99:1926–1935.
   Google Scholar
• GOHLKE P, PEES C, UNGER T: AT2 receptor stimulation increases aortic cyclic GMP in SUMP by a kinin-dependent mechanism. Hypertension (19910 31:349–355.
   Google Scholar
• SIRAGY HM, CAREY RM: The subtype-2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin. Invest. (1997) 100:264–269.
   PubMed Web of Science ®Google Scholar
• GREENE E, KREN S, HOSTETTER T: Role of aldosterone in the remnant kidney model in the rat. J Clin. Invest. (1996) 98:1063–1068.
   PubMed Web of Science ®Google Scholar
• BRILLA C, WEBER K: Miner alocor ticoid excess, dietary sodium and myocardial fibrosis. J Lab. Clin. Med. (1992) 120:893–901.
   PubMed Web of Science ®Google Scholar
• BJORCK S: The renin angiotensin system in diabetesmellitus. Scand. j Urol. Nephrol (1990) (Suppl.):126.
   Google Scholar
• PEREZ GO, LESPIER L, JACOBI J: Hyporeninemia andhypoaldosteronism in diabetes mellitus: A physiological and therapeutic study. Arch. Intern. Med. (1977) 137:852–855.
   PubMedGoogle Scholar
• GILBERT RE, WU LL, KELLY DJ et al.: Pathological expres-sion of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of the tubulointerstitialnephrosis. Am]. Pathol. (1999) 155:429–440.
   PubMed Web of Science ®Google Scholar
• ANDERSON S, JUNG FF, INGELFINGER JR: Renal renin-angiotensin system in diabetes: functional, immuno-histochemical and molecular biological correlations. Am. J. Physiol. (1993) 265:F477–F486.
   PubMed Web of Science ®Google Scholar
• CHOI KC, KIM NH, AN MR, KANG DG, KIM SW, LEE J:Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int. (1997) 52 (Suppl. 60):S23–S27.
   Google Scholar
• COOPER ME, RUMBLE J, KOMERS R, DU H-C, JANDELEIT K, CHOU ST: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes (1994) 43:1221–1228.
   PubMed Web of Science ®Google Scholar
• KENNEFICK TM, OYAMA TT, THOMPSON MM, VORA JP, ANDERSON S: Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am. Physiol. (1996) 271:F595–F602.
   PubMed Web of Science ®Google Scholar
• VORA J, OYAMA TT, THOPSON MM, ANDERSON S: Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes (1997) 46:107–112.
   PubMed Web of Science ®Google Scholar
• CAMPBELL DJ, KELLY DJ, WILKINSON-BERKA JL, COOPERME, SKINNER SL: Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int. (1999) 56:211–221.
   PubMed Web of Science ®Google Scholar
• WILKES BM: Reduced glomerular angiotensin IIreceptor density in diabetes mellitus in the rat: Time course and mechanism. Endocrinology (1 98 7) 1 20:1291-1298.
   Google Scholar
• SECHI LA, GRIFFIN CA, SCHAMBELAN M: The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes (1994) 43:1180–1184.
   PubMed Web of Science ®Google Scholar
• DEOLIVEIRA J, PRICE D, FISHER N et al.: Autonomy of the renin system in Type II diabetes: dietary sodium and renal hemodynamic response to ACE inhibition. Kidney Int. (1997) 52:771–777.
   PubMed Web of Science ®Google Scholar
• PRICE D, PORTER L, GORDON M et al.: The paradox of the low-renin state in diabetic nephropathy. j. Am. Soc. Nephrol. (1999) 10:2382–2391.
   PubMed Web of Science ®Google Scholar
• •This study and [41] explores the activity of the RAS in Type 2 diabetic patients.
   Google Scholar
• FREDERICH RJ, KAHN B, PEACH M, FLIER J: Tissue- specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension (1992) 1 9 :339–344.
   Google Scholar
• •This study and [40] explores the activity of the RAS in Type 2 diabetic patients.
   Google Scholar
• CASSIS L: Down regulation of the renin-angiotensinsystem in streprozotocin-diabetic rats. Am. J Physiol. (1992) 262:E105–E109.
   PubMed Web of Science ®Google Scholar
• DIET F, PRATT R, BERRY G, MOMOSE N, GIBBONS G, DZAU V: Increased accumulation of tissue ACE in humans atherosclerotic coronary artery disease. Circulation (1996) 94:2756–2767.
   PubMed Web of Science ®Google Scholar
• JAGER A, VAN HINSBERGH V, KOSTENSE P et al.: Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in Type II diabetes mellitus: the Hoorn study. Diabetes (2000) 49:485–491.
   PubMed Web of Science ®Google Scholar
• DE MATTIA G, CASSONE-FALDETTA M, BELLINI C et al.:Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am. J. Hypertens. (1998) 11:983–988.
   PubMed Web of Science ®Google Scholar
• TAKAHARA N, KASHIWAGI A, NISHIO Y et al: Oxidizedlipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia (1997) 40:662–670.
   PubMed Web of Science ®Google Scholar
• JOKL R, KLEIN R, LOPES-VIRELLA M, COLWELL J: Releaseof platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with Type II diabetes. Diabetes Care (1995) 18:1150–1155.
   PubMed Web of Science ®Google Scholar
• ERDOS EG: Conversion of angiotensin Ito angiotensin II. Ann. Rev. Med. (1976) 60:749–759.
   Google Scholar
• CAMPBELL DJ, KLADIS A, DUNCAN AM: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension (1994) 23:439–449.
   PubMed Web of Science ®Google Scholar
• IGNARRO LJ, BUGA GM, CHAUDHURI G: EDRF genera-tion and release from perfused bovine pulmonary artery and vein. Eur. j Pharmacol (1990) 149:79–88.
   Web of Science ®Google Scholar
• NAVAR LG, INSCHO EW, MAJID DSA, IMIG JD,HARRISON-BERNARD LM, MITCHELL KD: Paracrine regulation of the renal microcirculation. Physiol. Rev. (1996) 76:425–536.
   PubMed Web of Science ®Google Scholar
• GARG UC, HASSID A: Inhibition of rat mesangial cellmitogenesis by nitric oxide generating vasodilators. Am. J. Physic]. (1989) 257:F60–F66.
   Web of Science ®Google Scholar
• DENICOLA L, BLANTZ RC, GABBAI FB: Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J. Clin. Invest. (1992) 89:1248–1256.
   PubMed Web of Science ®Google Scholar
• LINZ W, SCHOLKENS BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes antihypertro-phic effect of ramipril. Br. J. Pharmacol. (1992) 105:771–772.
   PubMed Web of Science ®Google Scholar
• CHEN K, ZHANG X, DUNHAM EW, ZIMMERMAN BG: Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension. Hypertension (1996) 27:85–89.
   PubMed Web of Science ®Google Scholar
• FARHY RD, CARRETERO OA, HO K-L, SCICLI AG: Role ofkinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res. (1993) 72:1202–1210.
   PubMed Web of Science ®Google Scholar
• RHALEB N-E, YANG XP, SCICLI AG, CARRETERO OA: Roleof kinins and nitric oxide in antihypertensive effect of ramipril. Hypertension (1994) 23:865–868.
   PubMedGoogle Scholar
• WILCOX CS, CAROZO J, WELCH WJ: ATI and Tx A2 /PGH2receptors maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat. Am. J Physiol (1996) 271:R891–R896.
   PubMed Web of Science ®Google Scholar
• RHALEB N-E, PENG H, ALFIE ME, SHESELY EG,CARRETERO OA: Effect of ACE inhibitor on DOCA-salt-and aortic coarctation-induced hypertension in mice. Do kinin B2 receptors play a role? Hypertension (1999) 33:329–334.
   Google Scholar
• HORNIG B, KOHLER C, DREXLER H: Role of bradykininin mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115–1118.
   PubMed Web of Science ®Google Scholar
• GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl. J. Med. (1998) 339:1285–1292.
   PubMed Web of Science ®Google Scholar
• KOMERS R, COOPER ME: Acute renal hemodynamic effects of angiotensin converting enzyme inhibitors in diabetic hyperfiltration: The role of kinins. Am. J Physic)]. (1995) 268:F588–F594.
   Web of Science ®Google Scholar
• ALLEN TJ, CAO Z, YOUSSEF S, HULTHEN UL, COOPER ME:Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes (1997) 46:1612–1618.
   Google Scholar
• RUMBLE JR, KOMERS R, COOPER ME: Kinins or nitricoxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on vascular hypertrophy in the rat. J Hypertens. (1996) 14:601–607.
   PubMed Web of Science ®Google Scholar
• CHAPPEL MC, PIRRO MT, SYKES A, FERRARIO CM: Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension (1998) 31:362–367.
   PubMed Web of Science ®Google Scholar
• FERRARIO CM, CHAPPELL MC, TALLANT A, BROSNIHANKB, DIZ DI: Counterregulatory actions of angiotensin-(1-7). Hypertension (1997) 30:535–541.
   PubMed Web of Science ®Google Scholar
• KOHARA K, BROSNIHAN KB, FERRARIO CM: Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides (1993) 14:883–891.
   PubMed Web of Science ®Google Scholar
• CAMPBELL DJ, DUNCAN AM, KLADIS A, HARRAP SB: Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension (1995) 25:928–934.
   PubMed Web of Science ®Google Scholar
• IYER SN, FERRARIO CM, CHAPPELL MC: Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension (1998) 31:356–361.
   PubMed Web of Science ®Google Scholar
• BENTER IF, DIZ DI, FERRARIO CM: Cardiovascularactions of angiotensin-(1-7). Peptides (1993)14:679–684.
   PubMed Web of Science ®Google Scholar
• OSEI SY, AHIMA RS, MINKES RK, WEAVER JP, KHOSLA MC,KADOWITZ PJ: Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur. J. Pharmacol (1993) 235:35–42.
   Google Scholar
• PAULA RD, LIMA CV, KHOSLA MC, SANTOS RA: Angiotensin-(1-7) potentiates hypotensive effect of bradykinin in conscious rats. Hypertension (1995) 2 6:1154–1159.
   Google Scholar
• BROSNIHAN KB, LI P, FERRARIO CM: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension (1996) 27:523–528.
   PubMed Web of Science ®Google Scholar
• BENTER IF, FERRARIO CM, MORRIS M, DIZ DI: Antihyper-tensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am] Physiol. (1995) 269:H313–H319.
   PubMed Web of Science ®Google Scholar
• FERRARIO CM, MARTELL N, YUNIS C et al.: Characteriza-tion of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am. J. Hypertens. (1998) 11:137–146.
   PubMed Web of Science ®Google Scholar
• POLLARE T, LITHELL H, BERNE C: A comparison of theeffects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl. J. Med. (1989) 321:868–873.
   PubMed Web of Science ®Google Scholar
• TORLONE E, RAMBOTTI AM, PERRIELLO G et al.:ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and hypertension. Diabetologia (1991) 34:119–125.
   PubMed Web of Science ®Google Scholar
• PRINCE M, STUART C, PADIA M, BANDI Z, HOOLAND 0:Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patients. Arch. Intern. Med. (1 9 8 8) 148:2363-2368.
   Google Scholar
• FOGARI R, ZOPPI A, CORRADI L, LAZARRI P, MUGELLINIA, LUSARDI P: Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br. J. Clin. Pharmacol (1998) 46:467–471.
   PubMed Web of Science ®Google Scholar
• GALL M, ROSSING P, SKOTT P et al.: Placebo-controlledcomparison of captopril, metoprolol and hydrochlo-rothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. Am. J. Hypertens. (1992) 5:257–265.
   PubMed Web of Science ®Google Scholar
• KAWAI K, SUZUKI S, MURAYAMA Y, WATANABE Y, YAMASHITA K: Comparison of the effects of nivaldipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension. Diab. Res. Clin. Pract. (1992) 16:137–143.
   PubMed Web of Science ®Google Scholar
• STUMPE K, OVERLACK A: A new trial of efficacy, tolerability and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Am. J. Cardiol. (1993) 71:32E–37E.
   Google Scholar
• PETRIE J, MORRIS A, UEDA S et al.: Trandolapril does not improve insulin sensitivity in patients with hyperten-sion and Type 2 diabetes: a double-blind, placebo controlled crossover trial. j Clin. Endocrinol. Metab. (2000) 85:1882–1889.
   PubMed Web of Science ®Google Scholar
• LERCH M, WEIDMANN P, HO M et al.: Metabolic effects oftemocapril in hypertensive patients with diabetes mellitus Type 2. J. Cardiovasc. Pharmacol. (1999) 33:527–533.
   PubMed Web of Science ®Google Scholar
• ALLEMANN Y, BAUMANN S, JOST M et al.: Insulinsensitivity in normotensive subjects during angioten sin converting enzyme inhibition with fosinopril. Eur. j Gun. Pharm. (1992) 42:275–280.
   Web of Science ®Google Scholar
• RENELAND R, ALVAREZ E, ANDERSSON P, HAENNI A, BYBERG L, LITHELL H: Induction of insulin resistance by beta-blockade but not ACE-inhibition: long term treatment with atenolol or trandolapril. J. Hum. Hypertens. (2000) 14:175–180.
   PubMed Web of Science ®Google Scholar
• KODAMA J, KATAYAMA S, TANAKA K, ITABASHI A, KAWAZU S, ISHII J: Effect of captopril on glucose concentration: possible role of augmented postpran-dial forearm blood flow. Diabetes Care (1990) 13:1109–1111.
   PubMed Web of Science ®Google Scholar
• RETT K, JAUCH K, WICKLMAYR M, DIETZE G, FINK E, MENHERT H: Angiotensin converting enzyme inhibi-tors in diabetes: experimental and human experience. Am. Heart J. (1986) 62:59–64.
   Google Scholar
• HENRIKSEN E, JACOB S, KINNICK T, YOUNGBLOOD E, SCHMIT M, DIETZE G: ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradyki-nin and nitric oxide. Am. J. Physiol. (1999) 277:R332–R336.
   PubMed Web of Science ®Google Scholar
• DIETZE G: Modulation of the action of insulin in relation to the energy state in skeletal muscle. Possible involvement of kinins and prostaglandins. Mol Endocrinol. (1982) 25:127–149.
   Web of Science ®Google Scholar
• BALON TW, NADLER JL: Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl. Physiol. (1997) 82:359–363.
   PubMed Web of Science ®Google Scholar
• YOUNG ME, LEIGHTON B: Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem. J (1998) 329:73–79.
   PubMed Web of Science ®Google Scholar
• JAUCH K, HARTL W, GUENTHER B: Cap topril enhancesinsulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes melitus. Eur. j Clin. Invest. (1987) 17:448–454.
   PubMed Web of Science ®Google Scholar
• NUUTILA P, RAITAKARI M, LAINE H et al: Role of blood flow in reg-ulatinginsulin-stimulated glucose uptake in humans. J. Clin. Invest. (1996) 97:1741–1747.
   PubMed Web of Science ®Google Scholar
• DE WITT LM, PUTNEY JVV: Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx. FEBS Lett. (1983) 160:259–263.
   PubMed Web of Science ®Google Scholar
• WONG P, PRICE W, CHIU A, CARINI D, DUNCIA J: Nonpeptide angiotensin II receptor antagonists: Studies with EXP 9270 and Dup 753 IX. Hypertension (1990) 15:823–834.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, THAWANI H, KADES W et al.: Angiotensin II increases glucose utilisation during acute hyperinsulinemia via a hemodynamic mechanism. J. Clin. Invest. (1993) 92:720–726.
   PubMed Web of Science ®Google Scholar
• TOWNSEND RR, DIPETTE DJ: Pressor dose ofangiotensin II increase insulin-mediated glucose uptake in normotensive men. Am. J. Physiol. (1993) 265 :E362–E366.
   PubMed Web of Science ®Google Scholar
• O'CALLAGHAN C, KOMERSOVA K, LOUIS W: Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects. Hyperten-sion (1998) 31:104–109.
   PubMed Web of Science ®Google Scholar
• LAAKSO M, KARJALAINEN L, LEMPIAINEN-KUOSA P: Effects of losar tan on insulin sensitivity in hyperten-sive patients. Hypertension (1996) 28:392–396.
   PubMed Web of Science ®Google Scholar
• HIGASHIURA K, URA N, MIYAZAKI Y, SHIMAMOTO K: Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J. Hum. Hypertens. (1999) 13 (Suppl. 1):S71–S74.
   Google Scholar
• RODBY RA, ROHDE RD, CLARKE WR et al.: The irbesartan Type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol. Dial. Transplant. (2000) 15:487–497.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, JULIUS S et al.: Characteris-tics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction in Hypertension. Hypertension (1998) 32:989–997.
   PubMed Web of Science ®Google Scholar
• MANN J, JULIUS S: The Valsar tan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovas-cular events in hypertension. Rationale and design. Blood Pressure (1998) 7:176–183.
   PubMedGoogle Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• ••This analysis of the UKPDS, one of the largest clinical trialswith hypertensive Type 2 diabetic patients, showed that the degree of blood pressure reduction, rather than the choice of a particular agent, leads to decreased risk of cardiovas-cular events.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Efficacy of atenolol and captopril in reducing risk of macrovas-cular and microvascular complications in Type 2 diabetes: UKPDS 39. BMJ (1998) 317:713–720.
   PubMed Web of Science ®Google Scholar
• ••This analysis of the UKPDS demonstrated similar efficacy ofACEI and I3-blockers in preventing cardiovascular complica-tions in Type 2 diabetes.
   Google Scholar
• ESTACIO RO, BARRETT JW, HIATT WR, BIGGERSTAFF SL, GIFFORD N, SCHRIER RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl. J. Med. (1998) 338:645–652.
   PubMed Web of Science ®Google Scholar
• •This study suggests better effects of ACEI, compared with dihydropyridine calcium antagonist, in preventing cardio-vascular complications in Type 2 diabetes.
   Google Scholar
• TATTI P, PAHOR M, BYINGTON RT et al.: Outcome results of the fosinopril versus amlodipine cardiovas-cular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care (1998) 21:597–603.
   PubMed Web of Science ®Google Scholar
• •Similar to the ABCD, this trial suggests superior effect of ACEI compared with dihydropyridine calcium channel blockers, in preventing cardiovascular complications in Type 2 diabetes.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• TUOMILEHTO J, RASTENYTE D, BIRKENHAGER WH et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl. J. Med. (1999) 340:677–684.
   Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Cap topril Prevention Project (CAPPPP) randomized trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• ••This large trial demonstrated more beneficial effects of ACEIthan of conventional treatment on cardiovascular events in patients with moderate blood pressure control.
   Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al: Effects of an angiotensin-converting-inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• ••This trial included a large number of diabetic patients.Addition of ramipril reduced risk of cardiovascular and some microvascular complications.
   Google Scholar
• RAVID M, LANG R, RACHMANI R, LISCHNER M: long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch. Intern. Med. (1996) 156:286–289.
   Google Scholar
• •First larger study showing beneficial effects of ACEI in preventing the progression of microvascular complications in Type 2 diabetes.
   Google Scholar
• CHAN JC, COCKRAM CS, NICHOLLS MG, CHEUNG CK, SWAMINATHAN R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ (1992) 305:98–105.
   Google Scholar
• LACOURCIERE Y, NADEAU A, POIRIER L, TANCREDE G: Captopril or conventional therapy in hypertensive Type II diabetics. Three year analysis. Hypertension (1993) 21:786–794.
   Google Scholar
• SANO T, KAWAMURA T, MATSUMAE H et al: Effects of long-term enalapril treatment on persistent micro albuminuria in well controlled hypertensive and normotensive NIDDM patients. Diabetes Care (1994) 17:420–424.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, WIEGMANN TB, CNAAN A et al.: Renal protective effects on enalapril in hypertensive NIDDM: role ofbaseline albuminuria. Kidney/nt. (1994) 45 (Suppl.):S150–S155.
   Google Scholar
• BAKRIS GL, COPLEY JB, VICKNAIR N, SADLER R, LEURGANS S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. (1996) 50:1641–1650.
   PubMed Web of Science ®Google Scholar
• AGARDH CD, GARCIA-PUIG J, CHARBONNEL B, ANGELKORT B, BARNETT AH: Greater reduction of urinary albumin excretion in hypertensive Type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. (1996) 10:185–192.
   PubMed Web of Science ®Google Scholar
• MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Comparison between perindopril and nifedipine in normotensive patients with incipient diabetic nephro-pathy. BMJ (1991) 302:210–216.
   PubMed Web of Science ®Google Scholar
• VELUSSI M, BROCCO E, FRIGATO F et al: Effects of cilaza-pril and amlodipine on kidney function in hyperten-sive NIDDM patients. Diabetes (1996) 45:216–222.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, MOSCONI L, BIANCHI L et al: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtra-tion rate in non-insulin-dependent diabetic patients. Am. J. Kidney Dis. (1994) 24:753–761.
   PubMed Web of Science ®Google Scholar
• NIELSEN FS, ROSSING P, GALL MA, SKOTT P, SMIDT UM, PARVING H-H: long-term effects of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes (1997) 46:1182–1188.
   PubMed Web of Science ®Google Scholar
• RAVID M, BROSCH D, LEVI Z, BAR-DAYAN Y, RAVID D, RACHMANI R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus: A randomized, controlled trial. Ann. Int. Med. (1998) 128:982–988.
   PubMed Web of Science ®Google Scholar
• •This study suggests that early treatment with ACEI can prevent transition from normo- to microalbuminuria in Type 2 diabetic patients.
   Google Scholar
• BAKRIS GL, WEIR MR, DEQUATRO V, MCMAHON FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. (1998) 54:1283–1289.
   PubMed Web of Science ®Google Scholar
• FOGARI R, ZOPPI A, CORRADI L et al: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with Type II diabetes and impaired renal function. J. Hum. Hypertens. (1999) 13:47–53.
   PubMed Web of Science ®Google Scholar
• •This study shows similar nephroprotective effect of ACEI and dihydropyridine calcium channel blocker in a relatively large number of patients with Type 2 diabetes.
   Google Scholar
• CHAN JCN, KO GTC, LEUNG DHY et al:long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive 2 diabetic patients. Kidney Int. (2000) 57:590–600.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC, YUSUF S, MANN JFE et al: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• ••A substudy of the HOPE focusing on renal outcome inmostly Type 2 diabetic patients. This analysis does not suggest such a strong preventive potential of the ACEI as observed in cardiovascular end-points.
   Google Scholar
• DINNEEN SF, GERSTEIN HC: The association of microal-buminuria and mortality in non-insulin-dependent diabetes mellitus. Arch. Intern. Med. (1997) 157:1413–1418.
   PubMed Web of Science ®Google Scholar
• JUILLERAT L, NUSSBERGER J, MENARD J et al: Determi-nants of angiotensin II generation during converting enzyme inhibition. Hypertension (1994) 16:564–572.
   Google Scholar
• ROUSSEAU MF, KONSTAM MA, BENEDICT CR: Progres-sion of left ventricular dysfunction secondary to coronary artery disease, sustained neurohumoral activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am. J Cardiol (1994) 73:488–493.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, MAN IN'T VELD AJ, ADMIRAAL PJ et al: Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. (1992) 10:803–812.
   Web of Science ®Google Scholar
• URATA H, STROBEL F, GANTEN D: Widespread distribu-tion of human chymase. Hypertens. (1994)12:S17–S22.
   Web of Science ®Google Scholar
• JORDE UP, ENNEZAT PV, LISKER J et al: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• •An observation suggesting that maximal recommended doses of ACEI used in clinical medicine may not by sufficient to block effectively the RAS.
   Google Scholar
• KOMERS R, ANDERSON S: Optimal strategies for preventing progression of renal disease: Should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together? Curr. Hypertens. Rep. (2000) 2:465–472.
   PubMedGoogle Scholar
• MCKELVIE RS, YUSUF S, PERICAK D etal.: Comparison of candersartan, enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation (1999) 100:1056–1064.
   Google Scholar
• RUSSO D, PISANI A, BALLETTA MM et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. (1999) 33:851–856.
   PubMed Web of Science ®Google Scholar
• HEBERT LA, FALKENHEIM ME, NAHMAN NS, COSIO FG, O'DORISIO TM: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am. J. Nephrol (1999) 19:1–6.
   PubMed Web of Science ®Google Scholar
• COOPER ME, MOGENSEN CE: Role of candesartan, lisinopril and their combination on blood pressure and albuminuria in hypertensive microalbuminuric diabetic subjects. Am. J. Hypertens. (2000) 13:59A. Abstract.
   Google Scholar
• •Preliminary report of a study exploring the effects of combination ACEI and AT1B on blood pressure and microalbuminuria in Type 2 diabetes.
   Google Scholar
• GAEDE P, VEDEL P, PARVING H-H, PEDERSEN 0: Intensi-fied multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 randomized study. Lancet (1999) 353:617–622.
   PubMed Web of Science ®Google Scholar